Lentiviruses with trastuzumab bound to their envelopes can target and kill prostate cancer cells

Cancer Gene Therapy

Volumn 16, Issue 11, 2009, Pages 820-831

  Zhang, K X ^a   Moussavi, M ^a   Kim, C ^a   Chow, E ^a   Chen, I S ^b   Fazli, L ^a   Jia, W ^c   Rennie, P S ^a,d  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

HER 2; Lentivirus; Prostate cancer; Trastuzumab; Viral gene therapy

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GANCICLOVIR; LENTIVIRUS VECTOR; LUCIFERASE; MEMBRANE ANTIGEN; THYMIDINE KINASE; TRASTUZUMAB; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; CANCER CELL CULTURE; CELL KILLING; CELL STRAIN LNCAP; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LENTIVIRINAE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; TARGET CELL; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS ENVELOPE; VIRUS GENE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; LENTIVIRUS; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

LENTIVIRUS;

EID: 70350098239     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2009.28     Document Type: Article

References (65)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Chen FL, Armstrong AJ, George DJ. Cell signaling modifiers in prostate cancer. Cancer J 2008; 14: 40-45.
3. Damber JE, Aus G. Prostate cancer. Lancet 2008; 371: 1710-1721.
4. Shirakawa T, Fujisawa M, Gotoh A. Gene therapy in prostate cancer: past, present and future. Front Biosci 2008; 13: 2115-2119.
5. Carles J, Lloreta J, Salido M, Font A, Suarez M, Baena V et al. Her-2/neu expression in prostate cancer: a dynamic process? Clin Cancer Res 2004; 10: 4742-4745.
6. Di Lorenzo G, Autorino R, De Laurentiis M, Cindolo L, D'Armiento M, Bianco AR et al. HER-2/neu receptor in prostate cancer development and progression to androgen independence. Tumori 2004; 90: 163-170.
7. Hernes E, Fossa SD, Berner A, Otnes B, Nesland JM. Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Br J Cancer 2004; 90: 449-454.
8. Osman I, Mikhail M, Shuch B, Clute M, Cheli CD, Ghani F et al. Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression. J Urol 2005; 174: 2174-2177.
9. Shi XB, Ma AH, Tepper CG, Xia L, Gregg JP, Gandour-Edwards R et al. Molecular alterations associated with LNCaP cell progression to androgen independence. Prostate 2004; 60: 257-271.
10. Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000; 92: 1918-1925.
11. Zellweger T, Ninck C, Bloch M, Mirlacher M, Koivisto PA, Helin HJ et al. Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 2005; 113: 619-628.
12. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 2000; 60: 6841-6845.
13. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999; 5: 280-285.
14. Ziada A, Barqawi A, Glode LM, Varella-Garcia M, Crighton F, Majeski S et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 2004; 60: 332-337.
15. Schneider JW, Chang AY, Garratt A. Trastuzumab cardio-toxicity: speculations regarding pathophysiology and targets for further study. Semin Oncol 2002; 29(3 Suppl 11): 22-28.
16. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72: 8463-8471.
17. Morizono K, Xie Y, Ringpis GE, Johnson M, Nassanian H, Lee B et al. Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat Med 2005; 11: 346-352.
18. Aires da Silva F, Costa MJ, Corte-Real S, Goncalves J. Cell type-specific targeting with Sindbis pseudotyped lenti-viral vectors displaying anti-CCR5 single-chain antibodies. Hum Gene Ther 2005; 16: 223-234.
19. Strauss JH, Wang KS, Schmaljohn AL, Kuhn RJ, Strauss EG. Host-cell receptors for Sindbis virus. Arch Virol Suppl 1994; 9: 473-484.
20. Sharp JS, Nelson S, Brown D, Tomer KB. Structural characterization of the E2 glycoprotein from Sindbis by lysine biotinylation and LC-MS/MS. Virology 2006; 348: 216-223.
21. Mukhopadhyay S, Zhang W, Gabler S, Chipman PR, Strauss EG, Strauss JH et al. Mapping the structure and function of the E1 and E2 glycoproteins in alphaviruses. Structure 2006; 14: 63-73.
22. Ferreira D, Hernandez R, Horton M, Brown DT. Morphological variants of Sindbis virus produced by a mutation in the capsid protein. Virology 2003; 307: 54-66.
23. Zhang W, Mukhopadhyay S, Pletnev SV, Baker TS, Kuhn RJ, Rossmann MG. Placement of the structural proteins in Sindbis virus. J Virol 2002; 76: 11645-11658.
24. Kielian MC, Marsh M, Helenius A. Kinetics of endosome acidification detected by mutant and wild-type Semliki Forest virus. EMBO J 1986; 5: 3103-3109.
25. Bron R, Kendal AP, Klenk HD, Wilschut J. Role of the M2 protein in influenza virus membrane fusion: effects of amantadine and monensin on fusion kinetics. Virology 1993; 195: 808-811.
26. Smit JM, Bittman R, Wilschut J. Low-pH-dependent fusion of Sindbis virus with receptor-free cholesterol-and sphingolipid-containing liposomes. J Virol 1999; 73: 8476-8484.
27. Wahlberg JM, Garoff H. Membrane fusion process of Semliki Forest virus. I: low pH-induced rearrangement in spike protein quaternary structure precedes virus penetration into cells. J Cell Biol 1992; 116: 339-348.
28. Omar A, Koblet H. Semliki Forest virus particles containing only the E1 envelope glycoprotein are infectious and can induce cell-cell fusion. Virology 1988; 166: 17-23.
29. Sanz MA, Rejas MT, Carrasco L. Individual expression of Sindbis virus glycoproteins. E1 alone promotes cell fusion. Virology 2003; 305: 463-472.
30. Dubuisson J, Rice CM. Sindbis virus attachment: isolation and characterization of mutants with impaired binding to vertebrate cells. J Virol 1993; 67: 3363-3374.
31. Morizono K, Bristol G, Xie YM, Kung SK, Chen IS. Antibody-directed targeting of retroviral vectors via cell surface antigens. J Virol 2001; 75: 8016-8020.
32. Klimstra WB, Williams JC, Ryman KD, Heidner HW. Targeting Sindbis virus-based vectors to Fc receptor-positive cell types. Virology 2005; 338: 9-21.
33. Pariente N, Morizono K, Virk MS, Petrigliano FA, Reiter RE, Lieberman JR et al. A novel dual-targeted lentiviral vector leads to specific transduction of prostate cancer bone metastases in vivo after systemic administration. Mol Ther 2007; 15: 1973-1981.
34. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006; 3: 269-280.
35. Woraratanadharm J, Rubinchik S, Yu H, Fan F, Morrow SM, Dong JY. Highly specific transgene expression mediated by a complex adenovirus vector incorporating a prostate-specific amplification feedback loop. Gene Ther 2004; 11: 1399-1407.
36. Jin C, McKeehan K, Wang F. Transgenic mouse with high Cre recombinase activity in all prostate lobes, seminal vesicle, and ductus deferens. Prostate 2003; 57: 160-164.
37. Lowe SL, Rubinchik S, Honda T, McDonnell TJ, Dong JY, Norris JS. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells. Gene Ther 2001; 8: 1363-1371.
38. Andriani F, Nan B, Yu J, Li X, Weigel NL, McPhaul MJ et al. Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells. J Natl Cancer Inst 2001; 93: 1314-1324.
39. Lara Jr PN, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Kauderer C et al. HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial. Cancer 2002; 94: 2584-2589.
40. Savinainen KJ, Saramaki OR, Linja MJ, Bratt O, Tammela TL, Isola JJ et al. Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am J Pathol 2002; 160: 339-345.
41. Fulci G, Breymann L, Gianni D, Kurozomi K, Rhee SS, Yu J et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci USA 2006; 103: 12873-12878. (Pubitemid 44298654)
42. Fulci G, Dmitrieva N, Gianni D, Fontana EJ, Pan X, Lu Y et al. Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res 2007; 67: 9398-9406.
43. Collin SM, Martin RM, Metcalfe C, Gunnell D, Albertsen PC, Neal D et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol 2008; 9: 445-452.
44. Etzioni R, Feuer E. Studies of prostate-cancer mortality: caution advised. Lancet Oncol 2008; 9: 407-409.
45. Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol 2008; 15: 3866-3871.
46. Doxetaxel: new indication. Prostate cancer: a few more weeks. Prescrire Int 2006; 15: 6-7.
47. Wafa LA, Palmer J, Fazli L, Hurtado-Coll A, Bell RH, Nelson CC et al. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors. Hum Pathol 2007; 38: 161-170.
48. Berger R, Lin DI, Nieto M, Sicinska E, Garraway LA, Adams H et al. Androgen-dependent regulation of Her-2/ neu in prostate cancer cells. Cancer Res 2006; 66: 5723-5728.
49. Shi Y, Chatterjee SJ, Brands FH, Shi SR, Pootrakul L, Taylor CR et al. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations. BJU Int 2006; 97: 170-178.
50. Isharwal S, Miller MC, Epstein JI, Mangold LA, Humphreys E, Partin AW et al. Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy. Int J Cancer 2008; 123: 2636-2643.
51. Morris MJ, Reuter VE, Kelly WK, Slovin SF, Kenneson K, Verbel D et al. HER-2 profiling and targeting in prostate carcinoma. Cancer 2002; 94: 980-986.
52. Nahta R, Takahashi T, Ueno NT, Hung MC, Esteva FJ. P27(kip1) down-regulation is associated with trastuzu-mab resistance in breast cancer cells. Cancer Res 2004; 64: 3981-3986.
53. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943-1947.
54. Pourmand G, Ziaee AA, Abedi AR, Mehrsai A, Alavi HA, Ahmadi A et al. Role of PTEN gene in progression of prostate cancer. Urol J 2007; 4: 95-100.
55. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003; 4: 209-221.
56. Bastola DR, Pahwa GS, Lin MF, Cheng PW. Down-regulation of PTEN/MMAC/TEP1 expression in human prostate cancer cell line DU145 by growth stimuli. Mol Cell Biochem 2002; 236: 75-81.
57. Carracedo A, Pandolfi PP. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 2008; 27: 5527-5541.
58. King GD, Muhammad AK, Xiong W, Kroeger KM, Puntel M, Larocque D et al. High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic anti-adenovirus immunity. J Virol 2008; 82: 4680-4684.
59. Raki M, Hakkarainen T, Bauerschmitz GJ, Sarkioja M, Desmond RA, Kanerva A et al. Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus. Gene Ther 2007; 14: 1380-1388.
60. Straathof KC, Spencer DM, Sutton RE, Rooney CM. Suicide genes as safety switches in T lymphocytes. Cytotherapy 2003; 5: 227-230.
61. Golumbek PT, Hamzeh FM, Jaffee EM, Levitsky H, Lietman PS, Pardoll DM. Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, non-immunogenic tumor cell vaccines. J Immunother (1991) 1992; 12: 224-230.
62. Touraine RL, Ishii-Morita H, Ramsey WJ, Blaese RM. The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication. Gene Ther 1998; 5: 1705-1711.
63. Friedman A, Tian JP, Fulci G, Chiocca EA, Wang J. Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. Cancer Res 2006; 66: 2314-2319.
64. Hadaschik BA, Zhang K, So AI, Fazli L, Jia W, Bell JC et al. Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer. Cancer Res 2008; 68: 4506-4510.
65. Lee CY, Bu LX, Rennie PS, Jia WW. An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells. Cancer Gene Ther 2007; 14: 652-660.